• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCOVID-19 vaccines

Everything we know about the Johnson & Johnson COVID vaccine pause (so far)

By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
April 13, 2021, 12:58 PM ET

Tuesday’s surprise recommendation that health care providers pause the use of Johnson & Johnson’s COVID-19 vaccine left a lot of people scrambling. While the one-and-done shot has not been as widespread, in terms of distribution, as those by Moderna and Pfizer, nearly 7 million people already have received it.

The Food and Drug Administration and Centers for Disease Control and Prevention, which issued the guidance, are just beginning their investigations into the reports of potentially dangerous blood clots that occurred in six women in the days after vaccination. Both say the action was taken “out of an abundance of caution,” but that doesn’t answer a lot of questions. Here’s what the agencies have to say about some specific concerns.

I got the J&J vaccine a month (or more) ago. Should I be worried?

Health officials say the risk is very low to people who had the J&J vaccine more than a month ago. Any issues with clotting likely would have presented by now.

I just got a J&J vaccine shot recently. What should I be on alert for?

Again, the odds of developing the clots are low. But CDC Principal Deputy Director Anne Schuchat is suggesting people look for symptoms including severe headache, abdominal pain, leg pain, and shortness of breath. If you develop these within three weeks of getting your J&J shot, contact your health care provider and seek treatment.

She notes, though, that the flu-like symptoms that occur after receiving the vaccine are not things to worry about.

How long will this pause last?

That’s not known precisely right now, but Janet Woodcock, acting FDA commissioner, says “we expect it to be a matter of days.” The CDC says it’s committing to an expeditious review of the available information and an aggressive outreach to physicians so they’ll know how to diagnose, treat, and report issues.

Does this mean I can’t get the J&J COVID vaccine at all now?

No, but it’s probably better to wait. The recommendation is not a mandate, says Dr. Peter Marks, director of the FDA’s center for biologics evaluation and research. “If an individual health care provider has talked with a patient and they determine that the benefit/risk for that patient is appropriate, we’re not going to stop that provider from administering the vaccine.”

That said, expect most mass vaccination sites and pharmacies to follow the advice of the FDA and CDC for now.

I was supposed to get vaccinated this week. What do I do now?

If you have an appointment this week to get the J&J shot, check with your health care provider. Some are already shifting people over to Pfizer or Moderna. Others will reschedule you for another day in the near future, when a Pfizer or Moderna shot is available.

Important: If you have an J&J appt at a NY State-run vax site today (e.g. Javits, Aqueduct), you should still go and you will be offered Pfizer instead.

— Mark D. Levine (@MarkLevineNYC) April 13, 2021

“This may be a bit bumpy,” Schuchat says. “But we do want to make sure people who are scheduled to get vaccinations will be able to get [one] when vaccines are available.”

Are the clots associated with the J&J vaccine fatal?

Of the six cases that have been reported so far, one was fatal and one patient is in critical condition, officials say.

Should I be worried about blood clots with the Moderna or Pfizer vaccine?

The FDA and CDC say there have been no reports of any clotting issues with the other two vaccines being distributed in the U.S. right now. And, to date, there have been over 180 million injections of those, which should allay fears of a similar reaction.

Why did the pause of J&J’s vaccine seemingly come with no warning?

Even the FDA admits this was a sudden action. It comes down to transparency and wanting to prevent possible additional cases.

“I wish we had more time to get everyone prepared and this could have gone even more smoothly,” Woodcock says. “As we learned about the issue…it was clear to us that we needed to alert the public…The decision was based on events that might occur between when we made that realization and when we got the word out.”

What about the European rollout of J&J’s vaccine?

Johnson & Johnson announced Tuesday that it would be proactively delaying the rollout of the vaccine in Europe and would review the cases with European health authorities.

About the Author
By Chris MorrisFormer Contributing Writer

Chris Morris is a former contributing writer at Fortune, covering everything from general business news to the video game and theme park industries.

See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Simple App Review (2026): Expert Tested and Reviewed
Healthmeal delivery
Simple App Review (2026): Expert Tested and Reviewed
By Emily PharesApril 30, 2026
2 hours ago
Premium card perks are ‘designed to create a win-win-win for everyone’ but customers are paying with heavy annual fees and data
Personal FinancePersonal Finance Evergreen
Premium card perks are ‘designed to create a win-win-win for everyone’ but customers are paying with heavy annual fees and data
By Catherina GioinoApril 30, 2026
3 hours ago
hoskins
Commentaryoffices
Gensler Co-Chair: Hot-desking was supposed to save money. It may be costing you your culture
By Diane HoskinsApril 30, 2026
9 hours ago
raw milk
Politicsmilk
Risk of paralysis, bacteria, even death is no match for Americans’ thirst for raw milk
By Laura Ungar, Jonel Aleccia and The Associated PressApril 29, 2026
1 day ago
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
HealthDietary Supplements
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
By Christina SnyderApril 29, 2026
1 day ago
aging
HealthLongevity
We’re the CEOs of Peloton and the Hospital for Special Surgery. Living longer isn’t enough, we need to live better, too
By Bryan T. Kelly and Peter SternApril 29, 2026
1 day ago

Most Popular

Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
Success
Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
By Preston ForeApril 27, 2026
3 days ago
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
Banking
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
By Eva RoytburgApril 29, 2026
1 day ago
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
Economy
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
By Eleanor PringleApril 29, 2026
1 day ago
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
Big Tech
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
By Alexei OreskovicApril 29, 2026
18 hours ago
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
AI
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
By Sasha RogelbergApril 28, 2026
3 days ago
Elon Musk says saving for retirement is irrelevant because AI is going to create a world of abundance: 'It won't matter'
Future of Work
Elon Musk says saving for retirement is irrelevant because AI is going to create a world of abundance: 'It won't matter'
By Marco Quiroz-GutierrezApril 26, 2026
4 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.